Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.

Purpose To analyse feasibility, prognostic factors and patterns of recurrence after concurrent reirradiation and bevacizumab for recurrent high-grade gliomas. Patients and methods Between 2009 and 2015, 35 patients (median 57-year-old; 21 men, 14 women) with WHO grade III ( n = 11) or grade IV ( n = 24) gliomas were included in this retrospective and consecutive single-centre study. All patients received bevacizumab (median number of treatments: 12) concomitant with reirradiation (median dose: 45 Gy, median number of fractions: 18) for recurrence with median 22 months (range: 5.6–123.7 months) from first irradiation (median dose: 60 Gy). Results The median follow-up was 9.2 months from reirradiation. The median overall survival from reirradiation was 10.5 months (95% confidence interval [95% CI]: 4.9–16.1) and the progression-free survival from reirradiation was 6.7 months (95% CI: 2.9–10.5). The median overall survival from initial diagnosis was 44.6 months (95% CI: 32–57.1). No grade 3 toxicity or above was reported. Prognostic factors significantly correlated with better overall survival in univariate analysis were: age at least 55 ( P = 0.024), initial surgery ( P = 0.003), and 2 Gy equivalent dose (EQD2) at least 50 Gy at reirradiation ( P = 0.046). Twenty-two patients bevacizumab-naïve at time of reirradiation had a significantly increased overall survival from reirradiation compared to patients treated with reirradiation after bevacizumab failure (17.7 vs. 5.4 months, P < 0.001) as well as overall survival from initial diagnosis (58.9 vs. 33.5 months, P = 0.006). This outcome was similar in patients with initial glioblastomas ( P = 0.018) or anaplastic gliomas ( P = 0.021). There was no correlation between overall survival and gross tumour volume or planning target volume, frontal localization, or number of salvage therapies before reirradiation ( P > 0.05). Conclusions Concomitant reirradiation with bevacizumab in high-grade recurrent gliomas shows encouraging results in terms of survival and toxicities. Our data suggest that reirradiation should be favoured at initiation of bevacizumab, with EQD2 at least 50 Gy. [ABSTRACT FROM AUTHOR]